Keyword: Pfizer

Merck building

5. Merck

Merck had a major trial win last fall when its marketed checkpoint inhibitor Keytruda scored in first-line lung cancer patients. Just a few weeks later, it was given the nod from the FDA in this key, lucrative setting.